PT - JOURNAL ARTICLE AU - Ruth Johnson AU - Alexis V. Stephens AU - Sergey Knyazev AU - Lisa A. Kohn AU - Malika K. Freund AU - Leroy Bondhus AU - Brian L. Hill AU - Tommer Schwarz AU - Noah Zaitlen AU - Valerie A. Arboleda AU - Manish J. Butte AU - Bogdan Pasaniuc TI - Electronic health record signatures identify undiagnosed patients with Common Variable Immunodeficiency Disease AID - 10.1101/2022.08.03.22278352 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.03.22278352 4099 - http://medrxiv.org/content/early/2022/08/03/2022.08.03.22278352.short 4100 - http://medrxiv.org/content/early/2022/08/03/2022.08.03.22278352.full AB - One of the most common human inborn errors of immunity (IEI) is Common Variable Immunodeficiency (CVID), a heterogeneous group of disorders characterized by a state of functional and/or quantitative antibody deficiency and impaired B-cell responses. Although over 30 genes have been associated with the CVID phenotype, over half the CVID patients have no identified monogenic variant. There are currently no existing laboratory or genetic tests to definitively diagnose CVID and none are expected to be available in the near future. The extensive heterogeneity of CVID phenotypes causes patients with CVID to face a 5 to 15 years of delay in diagnosis and initiation of treatment, leading to a critical diagnosis odyssey. In this work, we present PheNet, an algorithm that identifies patients with CVID from their electronic health record data (EHR). PheNet computes the likelihood of a patient having CVID by learning phenotypic patterns, EHR-signatures, from a high-quality, clinically curated list of bona fide CVID patients identified from the UCLA Health system (N=197). The prediction model attains superior accuracy versus state-of-the-art methods, where we find that 57% of cases could be detected within the top 10% of individuals ranked by the algorithm compared to 37% identified by previous phenotype risk scores. In a retrospective analysis, we show that 64% of CVID patients at UCLA Health could have been identified by PheNet more than 8 months earlier than they had been clinically diagnosed. We validate our approach using a discovery dataset of ∼880K patients in the UCLA Health system to identify 74 of the top 100 patients ranked by PheNet score (top 0.01% PheNet percentile) as highly probable to have CVID in a clinical blinded chart review by an immune specialist.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by R01 AI153827.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCLA Institutional Review Board gave ethical approval for this work (IRB#20-002316) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-level patient records are not available due to privacy limitations. All summary statistics from the study are contained in the manuscript.